+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Liver Cirrhosis (Gastrointestinal) - Drugs In Development, 2021

  • ID: 5359614
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 178 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Baylx Inc
  • Candel Therapeutics
  • China Immunotech Co Ltd
  • Oncocross Co Ltd
  • PrimeGen Global Inc
  • Promethera Biosciences SA
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis (Gastrointestinal) - Drugs In Development, 2021, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis (Gastrointestinal) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 2, 12, 6, 1, 1, 16 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Baylx Inc
  • Candel Therapeutics
  • China Immunotech Co Ltd
  • Oncocross Co Ltd
  • PrimeGen Global Inc
  • Promethera Biosciences SA
  • Introduction
  • Liver Cirrhosis - Overview
  • Liver Cirrhosis - Therapeutics Development
  • Liver Cirrhosis - Therapeutics Assessment
  • Liver Cirrhosis - Companies Involved in Therapeutics Development
  • Liver Cirrhosis - Drug Profiles
Liver Cirrhosis - Dormant Projects

Liver Cirrhosis - Discontinued Products
  • Liver Cirrhosis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Liver Cirrhosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Liver Cirrhosis - Pipeline by Baylx Inc, 2021
  • Liver Cirrhosis - Pipeline by Bristol-Myers Squibb Co, 2021
  • Liver Cirrhosis - Pipeline by Candel Therapeutics, 2021
  • Liver Cirrhosis - Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, 2021
  • Liver Cirrhosis - Pipeline by CellionBioMed Inc, 2021
  • Liver Cirrhosis - Pipeline by China Immunotech Co Ltd, 2021
  • Liver Cirrhosis - Pipeline by D&D Pharmatech Co Ltd, 2021
  • Liver Cirrhosis - Pipeline by Elixirgen Therapeutics Inc, 2021
  • Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, 2021
  • Liver Cirrhosis - Pipeline by Galecto Inc, 2021
  • Liver Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, 2021
  • Liver Cirrhosis - Dormant Projects, 2021
  • Liver Cirrhosis - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Liver Cirrhosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Baylx Inc
  • Bristol-Myers Squibb Co
  • Candel Therapeutics
  • CAR-T (Shanghai) Biotechnology Co Ltd
  • CellionBioMed Inc
  • China Immunotech Co Ltd
  • Ochre Bio Ltd
  • Oncocross Co Ltd
  • Pharmicell Co Ltd
  • PrimeGen Global Inc
  • PRISM Pharma Co Ltd
  • Promethera Biosciences SA
  • Protgen Ltd
  • Resolution Therapeutics Ltd
  • Rohto Pharmaceutical Co Ltd
  • Shanghai Huicun Medical Technology Co Ltd
  • Shionogi & Co Ltd
  • Tonghua Dongbao Pharmaceutical Co Ltd
  • Tuohua Biological Technology Co Ltd
  • Versantis AG
  • VESSL Therapeutics Ltd
  • Xfibra Inc
Note: Product cover images may vary from those shown
Adroll
adroll